Cytotoxic T Lymphocyte Protein 4 - Pipeline Review, H2 2019

Cytotoxic T Lymphocyte Protein 4 - Pipeline Review, H2 2019

  • November 2019 •
  • 237 pages •
  • Report ID: 5830781 •
  • Format: PDF
Cytotoxic T Lymphocyte Protein 4 - Pipeline Review, H2 2019

Summary
According to the recently published report ’Cytotoxic T Lymphocyte Protein 4 - Pipeline Review, H2 2019’; Cytotoxic T Lymphocyte Protein 4 (Cytotoxic T Lymphocyte Associated Antigen 4 or CD152 or CTLA4) pipeline Target constitutes close to 64 molecules. Out of which approximately 63 molecules are developed by companies and remaining by the universities/institutes.

Cytotoxic T Lymphocyte Protein 4 (Cytotoxic T Lymphocyte Associated Antigen 4 or CD152 or CTLA4) - CTLA4 also known as CD152 is a protein receptor found on the surface of T cells. It functions as an immune checkpoint and down regulates the immune system. The affinity of CTLA4 for its natural B7 family ligands, CD80 and CD86, is considerably stronger than the affinity of their cognate stimulatory co-receptor CD28. Inhibition of receptor acts as a major negative regulator of T-cell responses.

The report ’Cytotoxic T Lymphocyte Protein 4 - Pipeline Review, H2 2019’ outlays comprehensive information on the Cytotoxic T Lymphocyte Protein 4 (Cytotoxic T Lymphocyte Associated Antigen 4 or CD152 or CTLA4) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type; that are being developed by Companies / Universities.

It also reviews key players involved in Cytotoxic T Lymphocyte Protein 4 (Cytotoxic T Lymphocyte Associated Antigen 4 or CD152 or CTLA4) targeted therapeutics development with respective active and dormant or discontinued projects. Currently, The molecules developed by companies in Pre-Registration, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical and Discovery stages are 1, 2, 8, 17, 1, 25 and 9 respectively. Similarly, the universities portfolio in Discovery stages comprises 1 molecules, respectively. Report covers products from therapy areas Oncology, Immunology and Infectious Disease which include indications Solid Tumor, Melanoma, Metastatic Melanoma, Non-Small Cell Lung Cancer, Breast Cancer, Colon Cancer, Gastric Cancer, Renal Cell Carcinoma, Small-Cell Lung Cancer, Colorectal Cancer, Head And Neck Cancer Squamous Cell Carcinoma, Adenocarcinoma Of The Gastroesophageal Junction, Cervical Cancer, Metastatic Breast Cancer, Nasopharyngeal Cancer, Squamous Non-Small Cell Lung Cancer, Bladder Cancer, Epithelial Ovarian Cancer, Fallopian Tube Cancer, Hepatocellular Carcinoma, Metastatic Colorectal Cancer, Metastatic Transitional (Urothelial) Tract Cancer, Ovarian Cancer, Peritoneal Cancer, Prostate Cancer, Transitional Cell Cancer (Urothelial Cell Cancer), Anal Cancer, Bile Duct Cancer (Cholangiocarcinoma), Gastroesophageal (GE) Junction Carcinomas, Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma), Metastatic Renal Cell Carcinoma, Muscle Invasive Bladder Cancer (MIBC), Non-Hodgkin Lymphoma, Recurrent Head And Neck Cancer Squamous Cell Carcinoma, Soft Tissue Sarcoma, Anaplastic Thyroid Cancer, Endometrial Cancer, Esophageal Cancer, Esophageal Squamous Cell Carcinoma (ESCC), Germ Cell Tumors, Lung Cancer, Lymphoma, Malignant Pleural Mesothelioma, Medullary Thyroid Cancer, Merkel Cell Carcinoma, Metastatic Hepatocellular Carcinoma (HCC), Metastatic Pancreatic Cancer, Multiple Myeloma (Kahler Disease), Myelodysplastic Syndrome, Neuroblastoma, Neuroendocrine Gastroenteropancreatic Tumors (GEP-NET), Osteosarcoma, Pancreatic Cancer, Pancreatic Ductal Adenocarcinoma, Salivary Gland Cancer, Sarcomas, Triple-Negative Breast Cancer (TNBC), Vaginal Cancer, Vulvar Cancer, Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia), Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia), Adenocarcinoma, Adenoid Cystic Carcinoma (ACC), Adrenal Gland Cancer, Adrenocortical Carcinoma (Adrenal Cortex Cancer), Advanced Malignancy, Basal Cell Carcinoma (Basal Cell Epithelioma), Bone Sarcoma, Chronic Lymphocytic Leukemia (CLL), Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia), Dedifferentiated Liposarcoma, Diffuse Large B-Cell Lymphoma, Dysgerminoma, Ependymoma, Epstein-Barr Virus (HHV-4) Infections, Ewing Sarcoma, Follicular Thyroid Cancer, Gallbladder Cancer, Germinomatous (Seminomatous) Germ Cell Tumors, Glioblastoma Multiforme (GBM), Gliosarcoma, Graft Versus Host Disease (GVHD), Head And Neck Cancer, Head And Neck Carcinoma, Hematological Tumor, High-Grade Glioma, Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer, Kaposi Sarcoma, Leukemia, Liver Cancer, Malignant Fibrous Histiocytoma, Malignant Mesothelioma, Medulloblastoma, Meningioma, Metastatic Biliary Tract Cancer, Metastatic Cancer, Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer, Metastatic Liver Cancer, Metastatic Lung Cancer, Metastatic Ovarian Cancer, Metastatic Prostate Cancer, Metastatic Uveal Melanoma, Non-Small Cell Lung Carcinoma, Nongerminomatous (Nonseminomatous) Germ Cell Tumors, Oral Cavity (Mouth) Cancer, Oropharyngeal Cancer, Papillary Renal Cell Carcinoma, Papillary Thyroid Cancer, Pediatric Diffuse Intrinsic Pontine Glioma, Penile Cancer, Primitive Neuroectodermal Tumor (PNET), Refractory Multiple Myeloma, Relapsed Multiple Myeloma, Rhabdomyosarcoma, Squamous Cell Carcinoma, Transitional Cell Carcinoma (Urothelial Cell Carcinoma), Ureter Cancer, Urethral Cancer, Urinary Tract Cancer.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope
- The report provides a snapshot of the global therapeutic landscape for Cytotoxic T Lymphocyte Protein 4 (Cytotoxic T Lymphocyte Associated Antigen 4 or CD152 or CTLA4)
- The report reviews Cytotoxic T Lymphocyte Protein 4 (Cytotoxic T Lymphocyte Associated Antigen 4 or CD152 or CTLA4) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in Cytotoxic T Lymphocyte Protein 4 (Cytotoxic T Lymphocyte Associated Antigen 4 or CD152 or CTLA4) targeted therapeutics and enlists all their major and minor projects
- The report assesses Cytotoxic T Lymphocyte Protein 4 (Cytotoxic T Lymphocyte Associated Antigen 4 or CD152 or CTLA4) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news and deals related to Cytotoxic T Lymphocyte Protein 4 (Cytotoxic T Lymphocyte Associated Antigen 4 or CD152 or CTLA4) targeted therapeutics

Reasons to buy
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand the targeted therapy areas and indications for Cytotoxic T Lymphocyte Protein 4 (Cytotoxic T Lymphocyte Associated Antigen 4 or CD152 or CTLA4)
- Identify the use of drugs for target identification and drug repurposing
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Cytotoxic T Lymphocyte Protein 4 (Cytotoxic T Lymphocyte Associated Antigen 4 or CD152 or CTLA4) development landscape
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
Loading...

We are very sorry, but an error occurred.
Please contact support@reportbuyer.com if the problem remains.